Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?

AIDS

Volumn 22, Issue 2, 2008, Pages 269-273

  Castelnuovo, Barbara ^a   Byakwaga, Hellen ^a   Menten, Joris ^c   Schaefer, Petra ^a   Kamya, Moses ^b   Colebunders, Robert ^c  

^a Infectious Diseases Institute   (Uganda)

^b MAKERERE UNIVERSITY   (Uganda)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Antiretroviral therapy; HIV; Monitoring; Papular pruritic eruption; Treatment failure; Viral load

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PAPULAR RASH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SCORING SYSTEM; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; COHORT STUDIES; EXANTHEMA; FEMALE; HIV-1; HUMANS; MALE; MIDDLE AGED; PRURITUS; QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 37549057971     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f313a9     Document Type: Article

References (25)

1. Liautaud B, Pape JW, DeHovitz JA, Thomas F, LaRoche AC, Verdier RI, et al. Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol 1989; 125:629-632.
2. Rosatelli JB, Machado AA, Roselino AM. Dermatoses among Brazilian HIV-positive patients: correlation with the evolutionary phases of AIDS. Int J Dermatol 1997; 36:729-734.
3. Boonchai W, Laohasrisakul R, Manonukul J, Kulthanan K. Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. Int J Dermatol 1999; 38:348-350.
4. Muyinda H, Seeley J, Pickering H, Barton T. Social aspects of AIDS-related stigma in rural Uganda. Health Place 1997; 3:143-147.
5. Colebunders R, Mann JM, Francis H, Bila K, Izaley L, Kakonde N, et al. Generalized papular pruritic eruption in African patients with human immunodeficiency virus infection. AIDS 1987; 1:117-121.
6. Hira SK, Wadhawan D, Kamanga J, Kavindele D, Macuacua R, Patil PS, et al. Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia. J Am Acad Dermatol 1988; 19:451-457.
7. Pallangyo KJ. Cutaneous findings associated with HIV disease including AIDS: experience from Sub Saharan Africa. Trop Doct 1992; 22 (Suppl 1):35-41.
8. Pitche P, Tchangai-Walla K, Napo-Koura G, Mijiyawa M, Agbere A, Tatagan A. Prevalence of skin manifestations in AIDS patients in the Lome-Tokoin University Hospital (Togo). Sante 1995; 5:349-352.
9. Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mt Sinai J Med 2001; 68:298-308.
10. Sanchez M, Fiotades J, Soter NA, Lee MM, Ponge-Wilson I, Moy J, et al. The characterization of HIV-associated papular eruptions. IXth International Conference on AIDS. Berlin, 6-11 June 1993 [abstract Nr. PO-B20-1887].
11. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Geneva: World Health Organization; 2006. http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf
12. Rosatelli JB, Roselino AM. Hyper-IgE, eosinophilia, and immediate cutaneous hypersensitivity to insect antigens in the pruritic papular eruption of human immunodeficiency virus. Arch Dermatol 2001; 137:672-673.
13. Resneck JS Jr, Van Beek M, Furmanski L, Oyugi J, LeBoit PE, Katabira E, et al. Etiology of pruritic papular eruption with HIV infection in Uganda. JAMA 2004; 292:2614-2621.
14. Buchness MR, Lim HW, Hatcher VA, Sanchez M, Soter NA. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome. Treatment with ultraviolet B phototherapy. N Engl J Med 1988; 318:1183-1186.
15. Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis. Results of an open, pilot trial. Arch Dermatol 1995; 131:1047-1050.
16. Harris DW, Ostlere L, Buckley C, Johnson M, Rustin MH. Eosinophilic pustular folliculitis in an HIV-positive man: response to cetirizine. Br J Dermatol 1992; 126:392-394.
17. King C, Heon V, Berger T, Conant M. Itraconazole for the treatment of HIV-associated eosinophilic folliculitis. IXth International Conference on AIDS. Berlin, 6-11 June 1993 [abstract Nr. PO-B20-1873].
18. Blauvelt A, Plott RT, Spooner K, Stearn B, Davey RT, Turner ML. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. Arch Dermatol 1995; 131:360-361.
19. Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome. Report of three cases. J Am Acad Dermatol 1986; 14:1020-1022.
20. Cutler TP. Eosinophilic pustular folliculitis. Clin Exp Dermatol 1981; 6:327-332.
21. Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33:837-838.
22. Toutous-Trellu L, Abraham S, Pechere M, Chavaz P, Lubbe J, Schiffer V, et al. Topical tacrolimus for effective treatment of eosinophilic folliculitis associated with human immunodeficiency virus infection. Arch Dermatol 2005; 141:1203-1208.
23. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
24. Colebunders R, Moses KR, Laurence J, Shihab HM, Semitala F, Lutwama F, et al. A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis 2006; 6:53-59.
25. Maurer TA. Dermatologic manifestations of HIV infection. Top HIV Med 2005; 13:149-154.